These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29882016)

  • 61. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
    Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
    Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
    Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
    Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.
    Rademacher BL; Matkowskyj KA; LaCount ED; Carchman EH
    Eur J Cancer Prev; 2019 Nov; 28(6):483-491. PubMed ID: 30888976
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
    Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
    Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
    J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
    Bryce AH; Rao R; Sarkaria J; Reid JM; Qi Y; Qin R; James CD; Jenkins RB; Boni J; Erlichman C; Haluska P
    Invest New Drugs; 2012 Oct; 30(5):1934-41. PubMed ID: 21881915
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W; Fu W; Hu L
    Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
    Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ; Cockerill A; Fancourt C; Schmidt E; Moasser MM; Rugo HS; Melisko ME; Ko AH; Kelley RK; Korn WM; Esserman LJ; van't Veer L; Yau C; Wolf DM; Munster PN
    Breast Cancer Res Treat; 2016 Feb; 155(3):521-30. PubMed ID: 26875185
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
    Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
    de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
    Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
    Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.